MOUNTAIN VIEW, Calif., May 9, 2011 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM) today announced its financial results for the quarter ended March 31, 2011.
First Quarter 2011 Results
- Revenue of $6.8 million, as compared to $0.3 million reported in the first quarter of 2010.
- Costs and operating expenses of $18.9 million, as compared to $14.6 million in the first quarter of 2010.
- Net loss of $12.5 million, as compared to $14.3 million in the first quarter of 2010.
In the first quarter of 2011 the company recorded $6.6 million for costs of services, generating a gross margin for the quarter of $0.3 million. This is a transition from prior periods, when the company incurred start-up production costs to support its sequencing service. Start-up production costs in the first quarter of 2010 were $4.1 million.
Research and development expenses were $6.8 million during the first quarter of 2011, compared to $6.2 million in the first quarter of 2010. Sales and marketing expenses were $2.7 million during the first quarter of 2011, compared to $1.2 million in the first quarter of 2010.
"We have continued to make steady progress in growing our business. In the quarter, we delivered more than 600 genomes to our customers, enhanced our offering by reducing DNA input requirements and turnaround time, continued to improve both the cost and scale of the service, and expanded our commercial capabilities," said Clifford Reid, chairman, president and CEO of Complete Genomics.
The order backlog at March 31, 2011 was over 2,000 genomes, which the company believes could result in approximately $15 million in revenue over the next twelve months. Pricing of genome services starts at $9,500 per genome for small order sizes to between $5,000 to $7,500 per genome for orders in the hundreds of genomes. The company ended the first quarter of 2011 with $68.8 million in cash. The company's cash position reflects the completion of a $20 million loan agreement with Oxford Finance Corporation. $7.4 million of the Oxford loan was used to repay the balance of an existing loan with Comerica.
Highlights since the Company's Last Earnings Release
- For genomes sequenced during the first quarter, our median call rate was over 96% of the genome. Median turnaround time for data results was 70 days.
- The company provided the research community with access to 69 complete, high-coverage human genome sequences.
Q2 2011 Outlook
In the second quarter of 2011, the company expects to recognize revenue for more than 900 genomes.
Conference Call
Complete Genomics will host a conference call on May 9, 2011 at 2:00 p.m. PDT to discuss its financial results for the quarter. The conference dial in numbers are US: (877) 844 - 6890 or International: (760) 298 - 5092 (Conference ID: 65709967). A live audio webcast of the call will also be available in the Investor Relations section of the Complete Genomics website at http://ir.completegenomics.com/.
An audio webcast replay of the conference call will also be available in the Investor Relations section of the Complete Genomics website approximately two hours after the call and for 30 days thereafter.
About Complete Genomics
Complete Genomics is a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines our proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this innovative, end-to-end, outsourced solution as CGA™ Service, and provide customers with data that is immediately ready to be used for genome-based research. Additional information can be found at www.completegenomics.com.
The Complete Genomics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8216
Forward Looking Statements
Certain statements in this press release, including statements relating to backlog and future numbers of genomes to be sequenced, are forward looking statements that are subject to risks and uncertainties. Readers are cautioned that these forward looking statements are based on management's current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward looking statements: the company's limited operating history, delays in production due to technical issues, any failure to complete backlogged orders and recognize the associated revenue, any potential inability to increase yield and any problems maintaining relationships with its customers. More information on potential factors that could affect the Company's financial results can be found in its Annual Report on Form 10-K filed on March 30, 2011 and its Quarterly Report on Form 10-Q for the three months ended March 31, 2011, including those listed under the caption "Risk Factors". The Company disclaims any obligation to update information contained in these forward looking statements, whether as a result of new information, future events or otherwise.
| Complete Genomics, Inc. | ||
| Condensed Statements of Operations | ||
| (in thousands, except share and per share amounts) | ||
| (unaudited) | ||
| Three months ended | ||
| March 31, | ||
| 2011 | 2010 | |
| Revenue | $ 6,833 | $ 336 |
| Operating expenses: | ||
| Cost of revenues | 6,582 | --- |
| Start-up production costs | --- | 4,077 |
| Research and development | 6,808 | 6,169 |
| General and administrative | 2,780 | 3,099 |
| Sales and marketing | 2,700 | 1,226 |
| Total operating expenses | 18,870 | 14,571 |
| Loss from operations | (12,037) | (14,235) |
| Interest expense | (340) | (311) |
| Interest and other income (expense), net | (84) | 210 |
| Net loss | $ (12,461) | $ (14,336) |
| Net loss per share attributed to common stockholders — basic and diluted | $ (0.48) | $ (51.15) |
| Weighted-average shares of common stock outstanding used in computing net loss per share—basic and diluted | 25,959,929 | 280,283 |
| Complete Genomics, Inc. | ||
| Condensed Balance Sheets | ||
| (in thousands) | ||
| (unaudited) | ||
| March 31, | December 31, | |
| 2011 | 2010 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $ 68,791 | $ 68,918 |
| Accounts receivable | 7,385 | 4,943 |
| Inventory | 3,176 | 3,980 |
| Prepaid expenses | 770 | 1,101 |
| Other current assets | 54 | 78 |
| Total current assets | 80,176 | 79,020 |
| Property and equipment, net | 24,256 | 23,843 |
| Other assets | 657 | 297 |
| Total assets | $ 105,089 | $ 103,160 |
| Liabilities, Convertible Preferred Stock and Stockholders' Deficit | ||
| Current liabilities | ||
| Accounts payable | $ 3,256 | $ 3,066 |
| Accrued liabilities | 3,788 | 3,102 |
| Notes payable, current | 1,412 | 5,780 |
| Deferred revenue | 7,021 | 5,739 |
| Total current liabilities | 15,477 | 17,687 |
| Notes payable, net of current | 22,724 | 7,521 |
| Deferred rent, net of current | 4,132 | 4,316 |
| Total liabilities | 42,333 | 29,524 |
| Convertible preferred stock | -- | -- |
| Common stock | 26 | 26 |
| Additional paid-in capital | 214,039 | 212,458 |
| Retained deficit | (151,309) | (138,848) |
| Total stockholders' equity (deficit) | 62,756 | 73,636 |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $ 105,089 | $ 103,160 |